The Importance of Self-Advocacy by Mara Klecker Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a…
Wade Watson, Stage III Melanoma Survivor A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
A Life Rewritten: Finding Strength in the Face of Melanoma By Mara Klecker Just Normal People Asked to describe his life before the first melanoma diagnosis—before losing an eye, undergoing…
Living Through TIL Therapy: A Personal Story By Mara Klecker Michael Moran shared his personal journey with melanoma to inspire, educate, and support others affected by this…
From Service to Survival: A Veteran’s Battle with Melanoma by Mara Klecker When a bump appeared on the top of his head in 2018, retired Marine Corps Chief Warrant…
From Diagnosis to Crown: Miss Pennsylvania’s Journey of Advocacy and Awareness By Mara Klecker Page Weinstein has a special request for photographers who take her portraits: Don’t edit out the scar…
Crafting Hope: Chris Krizek’s Journey from Cancer Patient to AIM Fundraiser with Wine Cork Creations By Mara Klecker Chris Krizek spent his career as the vice president of a nonprofit foundation, raising money for hospitals…
From Tanning Beds to Sun Safety: Brittanny Groover’s Journey of Melanoma Awareness and Advocacy By Mara Klecker Brittanny Groover grew up in a small town in Pennsylvania and spent her childhood outside, playing, riding…
From a Scare to Awareness: Lindsay Willis’s Mission to Educate on Melanoma Risks By Mara Klecker Lindsay Willis grew up hearing her mother’s warnings about skin damage and skin cancers and remembers hearing…
Stories of Strength: Three Melanoma Survivors Who Inspire Us All June marks National Cancer Survivor Month, a time to honor the remarkable resilience and strength of those who have battled…
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026 Promising 5-year data for the individualized neoantigen therapy, intismeran autogene, in combination with pembrolizumab (Keytruda)